This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Agu, R. U., Ugwoke, M. I., Armand, M., Kignet, R., and Verbaeke, N. 2001. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2:198–209.
Bartley, P. C., Bogoev, M., Larsen, J., and Philotheou, A. 2007. Long-term efficacy and safety of insulin detemir versus NPH insulin in subjects with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: A 2-year, randomized, controlled trial. Diabetic Medicine (in press).
Bolli, G., de Feo, P., Compagnucci, P., Cartechini, M. G., Angeletti, G., Santeusanio, F., Brunetti, P., and Gerich, J. E. 1983. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32:134–141.
Bolli, G. B., Dimitriadis, G. D., Pehling, G. B., Baker, B. A., Haymond, M. W., Cryer, P. E., and Gerich, J. E. 1984. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N. Engl. J. Med. 310:1706–1711.
Ceglia, L., Lau, J., and Pittas, A. G. 2006. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann. Intern. Med. 145:665–675.
The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Eng. J. Med. 329:977–986.
D’Armiento, M., Salabé, H., Vetrano, G., Scucchia, M., and Pachi, A. 1980. Decrease of thyroid antibodies during pregnancy. J. Endocrin. Invest. 3:437–438.
Exon, P. D., Dixon, K., and Malins, J. M. 1974. Insulin antibodies in diabetic pregnancy. Lancet 2 (7873):126–128.
Fabbri L. 2006. Pulmonary safety of inhaled insulins: a review of the current data. Curr. Med. Res. Opin. 22 (Suppl 3):21–28.
Fineberg, N. S., Fineberg, S. E., Anderson, J. H., Birkett, M. A., Gibson, R. G., and Hufferd, S. 1996. Immunologic effects of insulin lispro (Lys (B28), Pro (B29) human insulin) in IDDM and NIDDM patients previously treated with insulin. Diabetes 45:1750–1754.
Fineberg, S. E., Huang, J., Brunelle, R., Gulliya, K. S., and Anderson, J. H. 2003. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care 26:89–96.
Fineberg, S. E., Kawabata, T., Finco-Kent, D., Liu, C., and Krasner, A. 2005. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J. Clin. Endocrinol. Metab. 90:3287–3294.
Garg, S., Rosenstock, J., Silverman, B. L., Sun, B., Konkoy, C. S., de la Pena, A., and Muchmore, D. B. 2006. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 49:891–899.
Gönsslen, M. 1925. Über inhalation von insulin. Klin. Wochenschr. 4 (Jahrgang 2):71.
Hamalainen, A. M., Ronkainen, M. S., Akerblom, H. K., and Knip, M. 2000. Postnatal elimination of transplacentally acquired disease-associated antibodies in infants born to families with type 1 diabetes. The Finnish TRIGR Study group Trial to reduce IDDM in the genetically at risk. J. Clin. Endocrionol. Metab. 85: 4249–4253.
Heise, T., Bott, S., Tusek, C., Stephan, J.-A., Kawabata, T., Finco-Kent, D., Liu, C., and Krasner, A. 2005. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 28:2161–2169.
Heding, L. G., Marshall, M. O., Persson, B., Dahlquist, G., Thalme, B., Lindgren, F., Åkerblom, H. K., Rilva, A., Knip, M., Ludvigsson, J., Stenhammar, L., Strömberg, L., Søvik, O., Bævre, H., Wefring, K., Vidnes, J., Kjærgård, J. J., Bro, P., and Kaad, P. H. 1984. Immunogenicity of monocomponent human and porcine insulin in newly diagnosed Type 1 (insulin-dependent) diabetic children. Diabetologia 27:96–98.
Hermansen, K., Rönnemaa, T., Petersen, A. H., Bellaire, S., and Adamson, U. 2004. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 27:162–167.
Heubner, W., De Jongh, S. E., and Laquer, E. 1924. Über inhalation von insulin. Klin. Wochenschr. 3 (Jahrgang 51):2342–2343.
Holmberg, H., Mersebach, H., Kanc Hanzel, K., and Ludvigsson, J. 2007. Antibody response to insulin in children and adolescents with newly diagnosed type 1 diabetes. Diabetes 56 (Suppl 1):A476 (submitted for publication).
Jovanovic, L., Ilic, S., Pettitt, D. J., Hugo, K., Gutierrez, M., Bowsher, R. R., and Bastyr, E.J. 1999. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 22:1422–1427.
Jovanovic, L., Howard, C., Pettitt, D., Zisser, H., and Ospina P. 2005. Insulin aspart vs. regular human insulin in basal/bolus therapy for patients with gestational diabetes mellitus: safety and efficacy. Diabetologia 48 (Suppl 1):A317.
Lapolla, A., Dalfra, M. G., and Fedele, D. 2005. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? Diabetes Metab. Res. Rev. 21:241–52.
Lindholm, A., Jensen, L. B., Home, P. D., Raskin, P., Boehm, B. O., and Rastam, J. 2002. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 25:876–882.
Lindsay, R. S., Ziegler, A. G., Hamilton, B. A., Calder, A. A., Johnstone, F. D., and Walker, J. D. 2004. Type 1 diabetes-related antibodies in the fetal circulation: Prevalence and influence on cord insulin and birth weight in offspring of mothers with type 1 diabetes. J. Clin. Endocrinol. Metab. 89:3436–3439.
Marshall, M. O., Heding, L. G., Villumsen, J., Aakerblom, H. K., Baevre, H., Dahlquist, G., Kjaergaard, J. J., Knip, M., Lindgren, F., Ludvigsson, J., Persson, B., Stenhammar, L., Stromberg, L., Sovik, O., Thalme, B., Vidnes, J., and Wefring, K. 1988. Development of insulin antibodies, metabolic control and beta cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res. 9:169–175.
Mathiesen, E., Kinsley, B., McCance, D., Duran, S., Heller, S., Bellaire, S., and Raben, A. 2007. Maternal Hypoglycemia and Glycemic Control in Pregnancy: A Randomized Trial Comparing Insulin Aspart with Human Insulin in 322 Subjects with Type 1 Diabetes. Diabetes Care 30:771–776.
McCance, D., Damm, P., Mathiesen, E., Kaaja, R., Dunne, F., Hod, M., Jensen, L.E., and Mersebach, H. 2007. No increase in insulin antibodies during pregnancy and no clear evidence of transfer of insulin aspart across the placenta in pregnant women with type 1 diabetes. Diabetes 56 (Suppl 1):A22 (submitted for publication).
Menon, R. K., Cohen, R. M., Sperling, M. A., Cutfield, W. S., Mimouni, F., and Khoury, J. C. 1990. Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. Its role in fetal macrosomia. N. Engl. J. Med. 323:309–315.
Moses, R., Lunt, H., Bartley, P., O’Brien, R., Clauson, P., Vesterager, A., Wollmer, P., and Roberts, A. 2006. Periprandial inhaled human insulin via the AERx insulin Diabetes Management System (iDMS) vs. subcutaneous insulin aspart in type 1 diabetes. Diabetic Med. 23 (Suppl 4):338.
Roberts, A., Wilson, D., McElduff, A., Prins, J., Simpson, R., Haahr, H., Raastam, J., and Moses, R. 2006. Pharmacokinetics of inhaled human insulin via the AERx™ insulin Diabetes Management System (iDMS) in subjects with type 1 diabetes, naïve and non-naïve to inhaled insulin. Diabetic Med. 23 (Suppl 4):343.
Schernthaner, G. 1993. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155–165.
Spellacy, W. N., and Goetz, F. C. 1963. Insulin antibodies in pregnancy. Lancet 2:222–224.
Teeter, J. G., and Riese, R. J. 2006. Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am. J. Respir. Crit. Care Med. 173:1194–2000.
UKPDS Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853.
Quattrin, T., Berlanger, A., Bohannon, N. J., Schwartz, S. L., and Exubera Phase III Study Group. 2004. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2622–2627.
Velcovsky, H. G., and Federlin, K. F. 1982. Insulin-specific IgG and IgE antibody response in type 1 diabetes subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care 5 (Suppl 2):126–128.
Weiss, P. A., Kainer, F., and Haas J. 1998. Cord blood insulin to assess the quality of treatment in diabetic pregnancies. Early Hum. Dev. 51:187–195.
Wollmer, P., Peiber, T. R., Gall, M.-A., and Brunton, S. 2007. Delivering Needle-Free Insulin using AERx™iDMS (Insulin Diabetes Management System) Technology. Diabetes Technol. & Ther. 9 (Suppl 1):S57–64.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Mersebach, H., Smith, F., Sparre, T., Jensen, L.B. (2008). Case Study: Immunogenicity of Insulin. In: Weert, M.v., Møller, E.H. (eds) Immunogenicity of Biopharmaceuticals. Biotechnology: Pharmaceutical Aspects, vol VIII. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75841-1_8
Download citation
DOI: https://doi.org/10.1007/978-0-387-75841-1_8
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-75840-4
Online ISBN: 978-0-387-75841-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
